Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations

<h3>Objective</h3><p dir="ltr">To review the current evidence regarding pregnancy-related issues in multiple sclerosis (MS) and to provide recommendations specific for each of them.</p><h3>Research design and methods</h3><p dir="ltr">A sy...

Full description

Saved in:
Bibliographic Details
Main Author: Beatriz Canibaño (18102676) (author)
Other Authors: Dirk Deleu (4919410) (author), Boulenouar Mesraoua (16936932) (author), Gayane Melikyan (14777629) (author), Faiza Ibrahim (18102682) (author), Yolande Hanssens (14151507) (author)
Published: 2020
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513554565038080
author Beatriz Canibaño (18102676)
author2 Dirk Deleu (4919410)
Boulenouar Mesraoua (16936932)
Gayane Melikyan (14777629)
Faiza Ibrahim (18102682)
Yolande Hanssens (14151507)
author2_role author
author
author
author
author
author_facet Beatriz Canibaño (18102676)
Dirk Deleu (4919410)
Boulenouar Mesraoua (16936932)
Gayane Melikyan (14777629)
Faiza Ibrahim (18102682)
Yolande Hanssens (14151507)
author_role author
dc.creator.none.fl_str_mv Beatriz Canibaño (18102676)
Dirk Deleu (4919410)
Boulenouar Mesraoua (16936932)
Gayane Melikyan (14777629)
Faiza Ibrahim (18102682)
Yolande Hanssens (14151507)
dc.date.none.fl_str_mv 2020-02-06T03:00:00Z
dc.identifier.none.fl_str_mv 10.1080/21556660.2020.1721507
dc.relation.none.fl_str_mv https://figshare.com/articles/journal_contribution/Pregnancy-related_issues_in_women_with_multiple_sclerosis_an_evidence-based_review_with_practical_recommendations/27827400
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Biomedical and clinical sciences
Neurosciences
Pharmacology and pharmaceutical sciences
Reproductive medicine
Multiple sclerosis
pregnancy
breastfeeding
delivery
newborn
disease-modifying therapy
postpartum
dc.title.none.fl_str_mv Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
dc.type.none.fl_str_mv Text
Journal contribution
info:eu-repo/semantics/publishedVersion
text
contribution to journal
description <h3>Objective</h3><p dir="ltr">To review the current evidence regarding pregnancy-related issues in multiple sclerosis (MS) and to provide recommendations specific for each of them.</p><h3>Research design and methods</h3><p dir="ltr">A systematic review was performed based on a comprehensive literature search.</p><h3>Results</h3><p dir="ltr">MS has no effect on fertility, pregnancy or fetal outcomes, and pregnancies do not affect the long-term disease course and accumulation of disability. There is a potential risk for relapse after use of gonadotropin-releasing hormone agonists during assisted reproduction techniques. At short-term, pregnancy leads to a reduction of relapses during the third trimester, followed by an increased risk of relapses during the first three months postpartum. Pregnancies in MS are not <i>per se</i> high risk pregnancies, and MS does not influence the mode of delivery or anesthesia unless in the presence of significant disability. MRI is not contraindicated during pregnancy; however, gadolinium contrast media should be avoided whenever possible. It is safe to use pulse dose methylprednisolone infusions to manage acute disabling relapses during pregnancy and breastfeeding. However, its use during the first trimester of pregnancy is still controversial. Women with MS should be encouraged to breastfeed with a possible favorable effect of exclusive breastfeeding. Disease-modifying drugs can be classified according to their potential for pregnancy-associated risk and impact on fetal outcome. Interferon beta (IFNβ) and glatiramer acetate (GA) may be continued until pregnancy is confirmed and, after consideration of the individual risk-benefit if continued, during pregnancy. The benefit of continuing natalizumab during the entire pregnancy may outweigh the risk of recurring disease activity, particularly in women with highly active MS. GA and IFNβ are considered safe during breastfeeding. The use of natalizumab during pregnancy or lactation requires monitoring of the newborn.</p><h3>Conclusions</h3><p dir="ltr">This review provides current evidence and recommendations for counseling and management of women with MS preconception, during pregnancy and postpartum.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Drug Assessment<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/21556660.2020.1721507" target="_blank">https://dx.doi.org/10.1080/21556660.2020.1721507</a></p>
eu_rights_str_mv openAccess
id Manara2_ba2e62160ed3f05832841564d8c9d435
identifier_str_mv 10.1080/21556660.2020.1721507
network_acronym_str Manara2
network_name_str Manara2
oai_identifier_str oai:figshare.com:article/27827400
publishDate 2020
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendationsBeatriz Canibaño (18102676)Dirk Deleu (4919410)Boulenouar Mesraoua (16936932)Gayane Melikyan (14777629)Faiza Ibrahim (18102682)Yolande Hanssens (14151507)Biomedical and clinical sciencesNeurosciencesPharmacology and pharmaceutical sciencesReproductive medicineMultiple sclerosispregnancybreastfeedingdeliverynewborndisease-modifying therapypostpartum<h3>Objective</h3><p dir="ltr">To review the current evidence regarding pregnancy-related issues in multiple sclerosis (MS) and to provide recommendations specific for each of them.</p><h3>Research design and methods</h3><p dir="ltr">A systematic review was performed based on a comprehensive literature search.</p><h3>Results</h3><p dir="ltr">MS has no effect on fertility, pregnancy or fetal outcomes, and pregnancies do not affect the long-term disease course and accumulation of disability. There is a potential risk for relapse after use of gonadotropin-releasing hormone agonists during assisted reproduction techniques. At short-term, pregnancy leads to a reduction of relapses during the third trimester, followed by an increased risk of relapses during the first three months postpartum. Pregnancies in MS are not <i>per se</i> high risk pregnancies, and MS does not influence the mode of delivery or anesthesia unless in the presence of significant disability. MRI is not contraindicated during pregnancy; however, gadolinium contrast media should be avoided whenever possible. It is safe to use pulse dose methylprednisolone infusions to manage acute disabling relapses during pregnancy and breastfeeding. However, its use during the first trimester of pregnancy is still controversial. Women with MS should be encouraged to breastfeed with a possible favorable effect of exclusive breastfeeding. Disease-modifying drugs can be classified according to their potential for pregnancy-associated risk and impact on fetal outcome. Interferon beta (IFNβ) and glatiramer acetate (GA) may be continued until pregnancy is confirmed and, after consideration of the individual risk-benefit if continued, during pregnancy. The benefit of continuing natalizumab during the entire pregnancy may outweigh the risk of recurring disease activity, particularly in women with highly active MS. GA and IFNβ are considered safe during breastfeeding. The use of natalizumab during pregnancy or lactation requires monitoring of the newborn.</p><h3>Conclusions</h3><p dir="ltr">This review provides current evidence and recommendations for counseling and management of women with MS preconception, during pregnancy and postpartum.</p><h2>Other Information</h2><p dir="ltr">Published in: Journal of Drug Assessment<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1080/21556660.2020.1721507" target="_blank">https://dx.doi.org/10.1080/21556660.2020.1721507</a></p>2020-02-06T03:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1080/21556660.2020.1721507https://figshare.com/articles/journal_contribution/Pregnancy-related_issues_in_women_with_multiple_sclerosis_an_evidence-based_review_with_practical_recommendations/27827400CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/278274002020-02-06T03:00:00Z
spellingShingle Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
Beatriz Canibaño (18102676)
Biomedical and clinical sciences
Neurosciences
Pharmacology and pharmaceutical sciences
Reproductive medicine
Multiple sclerosis
pregnancy
breastfeeding
delivery
newborn
disease-modifying therapy
postpartum
status_str publishedVersion
title Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
title_full Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
title_fullStr Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
title_full_unstemmed Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
title_short Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
title_sort Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations
topic Biomedical and clinical sciences
Neurosciences
Pharmacology and pharmaceutical sciences
Reproductive medicine
Multiple sclerosis
pregnancy
breastfeeding
delivery
newborn
disease-modifying therapy
postpartum